Trials / Completed
CompletedNCT00672282
Casodex vs Placebo in Non-Metastatic Early Prostate Cancer
A Randomized, Double-Blind, Parallel-Group Trial Comparing Casodex 150mg Once Daily With Placebo in Patients With Non-Metastatic Prostate Cancer.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,218 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to study the effect of adjuvant or immediate hormonal therapy, versus placebo, in subjects who have either undergone a primary therapy (principally radical prostatectomy or radiotherapy) or who were otherwise to be managed by watchful waiting.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bicalutamide | 150mg p.o. daily |
| DRUG | Placebo |
Timeline
- Start date
- 1995-10-01
- Completion
- 2008-08-01
- First posted
- 2008-05-06
- Last updated
- 2009-05-27
Locations
54 sites across 4 countries: Denmark, Finland, Norway, Sweden
Source: ClinicalTrials.gov record NCT00672282. Inclusion in this directory is not an endorsement.